Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeted therapy for multiple myeloma.

K C Anderson1

  • 1Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

Seminars in Hematology
|August 7, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A high-throughput platform for biophysical antibody developability assessment to enable AI/ML model training.

mAbs·2025
Same author

Retraction Note: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide.

Leukemia·2024
Same author

Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials.

Seminars in hematology·2023
Same author

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Leukemia·2019
Same author

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

Leukemia·2018
Same author

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Leukemia·2017
Same journal

The many facets of cardiopulmonary complications in sickle cell disease.

Seminars in hematology·2026
Same journal

Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.

Seminars in hematology·2026
Same journal

Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis.

Seminars in hematology·2026
Same journal

Telomeres biology disorders: the past, the present and the future.

Seminars in hematology·2026
Same journal

Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

Seminars in hematology·2026
Same journal

Evolving insights into mitochondrial presence in RBC in sickle cell disease: Red blood cell and reticulocyte pathophysiology, therapeutic strategies, and future directions.

Seminars in hematology·2026
See all related articles

Novel targeted therapies are crucial for treating incurable multiple myeloma (MM). Research focuses on genetic targeting, apoptosis induction, microenvironment modulation, immune enhancement, and new antigen discovery for improved patient outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Cancer Biology

Background:

  • Multiple myeloma (MM) is an incurable hematologic malignancy.
  • Conventional treatments have limitations, necessitating novel therapeutic strategies.
  • There is an urgent need for biologically based therapies for MM.

Purpose of the Study:

  • To review and highlight novel, biologically based therapies for multiple myeloma.
  • To discuss targeted treatment approaches currently in development or clinical evaluation for MM.
  • To emphasize the potential of these novel therapies to improve patient outcomes.

Main Methods:

  • Identification of genetic abnormalities in myeloma cells to enhance sensitivity to chemotherapy and radiation.
  • Interruption of tumor cell growth and induction of apoptosis through targeted signaling pathways.

Related Experiment Videos

  • Therapeutic strategies targeting both myeloma cells and their surrounding microenvironment.
  • Enhancement of both allogeneic and autologous immune responses against myeloma.
  • Characterization of novel myeloma antigens for the development of serotherapies.

    • Main Results:

    • Multiple targeted therapy strategies are under active investigation for multiple myeloma.
    • These approaches aim to overcome limitations of conventional treatments.
    • Combinations of targeted therapies with conventional treatments show promise.

    Conclusions:

    • Novel targeted therapies offer significant promise for improving outcomes in multiple myeloma.
    • These therapies address key biological aspects of myeloma, including genetic vulnerabilities and immune evasion.
    • Further development and clinical evaluation are essential to realize the full potential of these treatments for MM patients.